Navigation Links
VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells

Researchers at the Virginia Commonwealth University Massey Cancer Center have found a new signaling component that influences movement of human breast cancer cells toward epidermal growth factor.

In the August issue of the Journal of Biological Chemistry, researchers showed that epidermal growth factor, which plays a critical role in breast cancer progression, stimulates sphingosine kinases - SphK1 and SphK2 - a family of enzymes that forms the potent lipid mediator, sphingosine-1-phosphate, and that breast cancer cells are unable to move without these kinases.

"If we understood how tumor cells spread or metastasize, we would be able to design better tools to help treat cancers," said lead author Sarah Spiegel, Ph.D., chair and professor in the VCU Department of Biochemistry and co-leader of the Massey Cancer Center Cell Signaling program.

Spiegel, who is internationally recognized for her pioneering work on new lipid mediators that regulate cell growth and cell death, and her colleagues, first discovered the role of sphingosine-1-phosphate in cell growth regulation nearly a decade ago. While researchers know that SphK1 is stimulated by multiple growth factors, less is known about how SphK2 is regulated. Spiegel and her team are continuing this work to better understand the functions of these enzymes.

"Our work suggests that sphingosine kinases are potential new targets in cancer therapy," she said.


'"/>

Source:Virginia Commonwealth University


Page: 1

Related biology news :

1. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
2. VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum
3. Massey researchers induce cell death in leukemia
4. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
5. Jump-starting T Cells In Skin Cancer
6. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
7. Fox Chase Cancer Center scientists identify immune-system mutation
8. Breakthrough Microarray-based Technology for the Study of Cancer
9. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
10. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
11. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
Post Your Comments:
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
(Date:10/15/2014)... Life, is a non-traditional biophysics textbook and it describes ... a journey of discovery into biological systems and provides ... regulation. It is about how our genes make proteins ... billions of cells in an organism. It quantifies the ... which can be found on both large and small ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... and Honorary Lecturer in Cardiovascular Medicine at The University of ... only location in the UK where the trial is taking ... manufacturer, to take part in the trial as he specialises ... attacks. The other trial sites are in Australia, Belgium, ...
... the Joint Annual Meeting of the American Dairy Science Association ... take place in Indianapolis, IN from July 8 to 12, ... symposia on topics such as animal genetics, food science and ... a hands-on media training workshop on July 12. Animal ...
... are thrown away each year because the ,best before, ... cautious estimate, which means a lot of still-edible food ... packaging could ,test, whether the contents are still safe ... di Catania, CEA-Liten and STMicroelectronics have invented a circuit ...
Cached Biology News:Manchester patients take part in pioneering heart attack blood test trial 2Invention opens the way to packaging that monitors food freshness 2Invention opens the way to packaging that monitors food freshness 3
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... 20, 2014 , A major ... and the delivery of care has revealed changing trends ... inequalities in the provision of healthcare services across the ... by United European Gastroenterology (UEG), have been announced today ... awareness of the burden of GI disorders across ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... BRISBANE, Australia and SAN CLEMENTE, Calif., Oct. ... medical applications of bioimpedance,technology and Metagenics, Inc., ... foods, and therapeutic lifestyle change,programs, today announced ... United States and Canada. Metagenics, Australian affiliate, ...
... 6, 2008 at 3:00 p.m. EDT, ... Inc., a,biopharmaceutical company developing genetically-targeted therapies for,heart ... that,Richard Brewer, the company,s president and chief ... chairman and chief science and medical,officer, will ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier ... oncologists and the pharmaceutical industry,today announced that the ... interview on WallSt.net,s 3-Minute Press Show., The ... and the,significance of the company,s latest press release., ...
Cached Biology Technology:ImpediMed and Metagenics Announce Agreement 2ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 2ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 3ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 4ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 5[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2
...
... (X/R) Red System consists of concentrated ... and X/R Red Buffer. The X/R ... to produce red staining that may ... , Buffer, 100 mL , Chromogen, ...
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Mouse Cell Line Slides...
Biology Products: